Conference Coverage
Advertisement
Researchers assessed the real-world treatment patterns and clinical outcomes of HER+ BC brain metastases.
Daily oral administration of the agent brought favorable transfusion independence performance and overall safety.
Individuals with metaplastic breast cancer (MpBC) show a distinct molecular phenotype.
A study sought to characterize the molecular and immunological features of the androgen receptor in male breast cancer.
People with hereditary cancer pathogenic variants for breast cancer may elect to undergo bilateral mastectomy for prevention.
The combination of tucatinib and alpelisib is both tolerable and effective at treating patients with HER2-positive MBC.
Vibecotamab showed clinical activity in low-blast, high-risk myeloid diseases, including MDS and CMML.
Long-term safety and efficacy phase I/II findings are now being investigated in younger patients in an ongoing study.
Luspatercept led to decreases RBCT burden vs epoetin alfa in patients with LR-MDS.
A transcriptomic analysis saw CDK8 repression increase expression of myeloid differentiation and oncogenesis genes in HSPCs.
In a study, lack of response to the doublet was most prevalent in multi-hit TP53 as compared with wild type or single-hit.
Rapamycin can normalize erythroid differentiation in SF3B1-mutated MDS by acting upon the mTOR signaling pathway.
US FDA researchers analyzed randomized, controlled, multicenter MDS trials for connections between OS, EFS, CR, and PR.
The combination was well-tolerated and the recommended dose determined for the phase II component of an ongoing trial.
Cohort patients had at least one prior intervention with luspatercept, lenalidomide, an HMA or ESA, or were ESA-ineligible.
A new study shows that progression from low burden atrial fibrillation (AF) is associated with negative outcomes.
Individuals with cardiac implantable electronic devices have a higher risk of tricuspid regurgitation.
The U.S. FDA recently approved Attruby (acoramidis) for adults with ATTR-CM to reduce cardiovascular death, hospitalization.
A study highlights the significant HCRU and costs associated with ATTR-CM.
Promising long-term outcomes from the ongoing OLE of the ATTRibute-CM trial highlight the efficacy of acoramidis.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.